Orexin-A

Orexin-A (also known as hypocretin-1) is a 33-amino acid neuropeptide produced exclusively by a small cluster of approximately 10,000-80,000 neurons in the lateral hypothalamus of the mammalian brain. Despite this tiny cell population, orexin neurons project widely throughout the neuraxis - innervating the locus coeruleus, dorsal raphe, tuberomammillary nucleus, basal forebrain, and cortex - and exert profound effects on arousal, metabolism, and motivation. The discovery of orexin in 1998, simultaneously reported by two groups (de Lecea and Kilduff as "hypocretin"; Sakurai and Yanagisawa as "orexin"), was immediately followed by the landmark finding that orexin deficiency is the direct cause of narcolepsy with cataplexy in dogs, mice, and humans.

Orexin acts through two G-protein-coupled receptors: OX1R (selective for Orexin-A) and OX2R (activated by both Orexin-A and Orexin-B with roughly equal affinity). OX1R couples predominantly to Gq proteins to activate phospholipase C, while OX2R activates both Gs and Gq pathways. Both receptors depolarise target neurons and increase firing rate, consistent with orexin's general role as a wake-promoting excitatory system.

The neuropathology of narcolepsy type 1 provides the clearest evidence for orexin's essential role in sleep-wake regulation. In this disorder, which affects approximately 1 in 2,000 people, 90-95% of orexin-producing hypothalamic neurons are selectively destroyed by an autoimmune process (triggered by certain HLA genotypes and environmental factors including influenza infection and the AS03-adjuvanted Pandemrix H1N1 vaccine). The resulting orexin deficiency produces the four cardinal symptoms of narcolepsy: excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by emotion), sleep paralysis, and hypnagogic hallucinations. Measuring CSF orexin-A (< 110 pg/mL is diagnostic) is the gold standard test for narcolepsy type 1.

The wake-promoting effects of orexin are mediated through activation of all major aminergic arousal systems: orexin neurons stimulate noradrenaline release from the locus coeruleus, serotonin from the dorsal raphe, histamine from the tuberomammillary nucleus, acetylcholine from the basal forebrain, and dopamine from the ventral tegmental area. By activating all arousal neurotransmitter systems simultaneously, orexin maintains a coherent, stable waking state. The opposite functions of these neurons during non-REM and REM sleep - when orexin firing is minimal - allows the brain to transition into sleep without the destabilising cataplexy that occurs when orexin neurons are lost.

The remarkable finding that intranasal Orexin-A can restore cognitive function in sleep-deprived rhesus monkeys - achieving effects equivalent to modafinil with fewer cardiovascular side effects - has attracted intense interest for potential human applications. The practical challenge is that Orexin-A, like most large peptides, crosses the blood-brain barrier poorly via systemic routes. Intranasal delivery appears to exploit olfactory nerve and lymphatic pathways to deliver peptide directly to the CNS. Several groups have reported intranasal orexin-A experiments in humans with promising preliminary results for sleep-deprivation countermeasures.

The clinical translation of orexin biology has proceeded remarkably swiftly on the antagonist side. The orexin receptor antagonist suvorexant (Belsomra), approved by the FDA in 2014, was the first in the new class of "dual orexin receptor antagonists" (DORAs) for insomnia. Unlike traditional hypnotics (benzodiazepines, Z-drugs) which broadly suppress neural activity, DORAs work by blocking the wake-promoting orexin signal - allowing natural sleep to occur by reducing wake drive rather than forcing sedation. Lemborexant and daridorexant followed with approved indications, establishing orexin antagonism as a validated insomnia treatment approach with a differentiated mechanism.

The agonist side - orexin replacement therapy for narcolepsy - remains an unmet need. OX2R selective agonists and orexin peptide nasal spray formulations are in phase 1-2 clinical trials, as is AAV-based gene therapy to restore hypothalamic orexin production. The potential of orexin agonists extends beyond narcolepsy to military applications (sustained wakefulness under cognitive demand), shift work disorder, and potentially neurodegenerative diseases (orexin system dysfunction is documented in Alzheimer's and Parkinson's disease).